Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
Mallinckrodt
Medtronic
Dow

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Oteracil

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Oteracil?

Oteracil is an investigational drug.

There have been 66 clinical trials for Oteracil. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Quintiles, Inc.

There are eighty-six US patents protecting this investigational drug and eight hundred and twenty international patents.

Recent Clinical Trials for Oteracil
TitleSponsorPhase
Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction AdenocarcinomaRenJi HospitalPhase 2
A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerShanghai Henlius BiotechPhase 3
SOX-based CRT for Esophageal Cancer.Zhejiang Provincial People’s HospitalPhase 1/Phase 2

See all Oteracil clinical trials

Clinical Trial Summary for Oteracil

Top disease conditions for Oteracil
Top clinical trial sponsors for Oteracil

See all Oteracil clinical trials

US Patents for Oteracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Oteracil   Start Trial Chromane herbicides E. I. Du Pont de Nemours and Company (Wilmington, DE)   Start Trial
Oteracil   Start Trial Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)   Start Trial
Oteracil   Start Trial Salts of optically active 4-hydroxy-8(3-lower alkoxy-4-phenylsulfinylphenyl)pyrazolo(1,5-A)-1,3,5- triazines and a process for production thereof Otsuka Pharmaceutical Factory, Inc. (Tokushima, JP)   Start Trial
Oteracil   Start Trial Prodrugs for selective drug delivery   Start Trial
Oteracil   Start Trial Enzyme assay of biochemical substances Oriental Yeast Co., Ltd. (Tokyo, JP)   Start Trial
Oteracil   Start Trial Compositions, methods and kits for potentiating antitumor effect and for treating tumor Taiho Pharmaceutical Co., Ltd. (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Oteracil

Drugname Country Document Number Estimated Expiration Related US Patent
Oteracil Argentina 243522 2006-12-10   Start Trial
Oteracil Australia 8215287 2006-12-10   Start Trial
Oteracil Brazil 8706588 2006-12-10   Start Trial
Oteracil China 1021824 2006-12-10   Start Trial
Oteracil China 87107276 2006-12-10   Start Trial
Oteracil German Democratic Republic 270532 2006-12-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Johnson and Johnson
Dow
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.